CASSAVA SCIENCES INC. - COMMON STOCK

Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program

05 May 2022 09:00:03 By Nasdaq GlobeNewswire

Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference

25 Apr 2022 09:00:00 By Nasdaq GlobeNewswire

Webcast Details for Cassava Sciences’ Upcoming Fireside Chat

04 Apr 2022 09:00:01 By Nasdaq GlobeNewswire

Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th

30 Mar 2022 09:00:01 By Nasdaq GlobeNewswire

Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates

28 Feb 2022 16:03:00 By Nasdaq GlobeNewswire

FDA Denies Citizen Petitions Filed on Behalf of Short Selling Clients

10 Feb 2022 16:07:38 By Nasdaq GlobeNewswire

Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease

23 Dec 2021 09:00:00 By Nasdaq GlobeNewswire

Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication

21 Dec 2021 09:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease

18 Nov 2021 09:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Third Quarter 2021 Financial Results

10 Nov 2021 09:00:01 By Nasdaq GlobeNewswire

Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences’ Lead Drug Candidate

04 Nov 2021 09:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease

06 Oct 2021 08:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer’s Disease

22 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

Cassava Sciences to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference

09 Sep 2021 08:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Releases a Public Statement Regarding Recent Allegations

03 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients

27 Aug 2021 11:31:59 By Nasdaq GlobeNewswire

Cassava Sciences Responds to Allegations

25 Aug 2021 06:00:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

24 Aug 2021 08:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Second Quarter 2021 Financial Results

03 Aug 2021 08:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Conference Call for Second Quarter Financial Results

02 Aug 2021 19:54:18 By Nasdaq GlobeNewswire